Latest Insider Transactions at Blueprint Medicines Corp (BPMC)
This section provides a real-time view of insider transactions for Blueprint Medicines Corp (BPMC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Blueprint Medicines Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Blueprint Medicines Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 14
2020
|
Marion Dorsch Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,600
-23.17%
|
$547,400
$119.0 P/Share
|
|
Dec 14
2020
|
Marion Dorsch Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,600
+18.81%
|
$170,200
$37.11 P/Share
|
|
Dec 14
2020
|
Anthony L. Boral Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,000
-9.25%
|
$1,170,000
$117.8 P/Share
|
|
Dec 14
2020
|
Anthony L. Boral Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+20.77%
|
$150,000
$15.01 P/Share
|
|
Dec 14
2020
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
5,000
-3.41%
|
$595,000
$119.18 P/Share
|
|
Dec 14
2020
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.3%
|
$40,000
$8.8 P/Share
|
|
Dec 11
2020
|
Mark Alan Goldberg |
SELL
Open market or private sale
|
Direct |
5,455
-60.5%
|
$627,325
$115.0 P/Share
|
|
Dec 11
2020
|
Mark Alan Goldberg |
BUY
Exercise of conversion of derivative security
|
Direct |
5,455
+37.69%
|
$152,740
$28.15 P/Share
|
|
Dec 01
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,038
-4.82%
|
$113,142
$109.54 P/Share
|
|
Dec 01
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
900
+7.64%
|
$7,200
$8.8 P/Share
|
|
Dec 01
2020
|
Mark Alan Goldberg |
SELL
Open market or private sale
|
Direct |
5,454
-60.49%
|
$599,940
$110.0 P/Share
|
|
Dec 01
2020
|
Mark Alan Goldberg |
BUY
Exercise of conversion of derivative security
|
Direct |
5,454
+37.69%
|
$152,712
$28.15 P/Share
|
|
Nov 16
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,700
-14.55%
|
$170,000
$100.92 P/Share
|
|
Nov 16
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+6.77%
|
$8,500
$5.34 P/Share
|
|
Nov 16
2020
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
20,000
-3.25%
|
$1,960,000
$98.85 P/Share
|
|
Nov 16
2020
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+11.02%
|
$160,000
$8.8 P/Share
|
|
Nov 16
2020
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
409
-0.95%
|
$40,900
$100.27 P/Share
|
|
Nov 16
2020
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
409
+0.94%
|
$14,724
$36.05 P/Share
|
|
Nov 03
2020
|
Christina Rossi CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
345
-1.69%
|
$34,155
$99.69 P/Share
|
|
Nov 03
2020
|
Charles A Rowland Jr Director |
SELL
Open market or private sale
|
Direct |
5,522
-23.34%
|
$541,156
$98.52 P/Share
|
|
Nov 03
2020
|
Charles A Rowland Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,522
+37.81%
|
$49,698
$9.46 P/Share
|
|
Nov 02
2020
|
Charles A Rowland Jr Director |
SELL
Open market or private sale
|
Direct |
4,478
-55.7%
|
$443,322
$99.11 P/Share
|
|
Nov 02
2020
|
Charles A Rowland Jr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,478
+35.77%
|
$40,302
$9.46 P/Share
|
|
Oct 23
2020
|
Anthony L. Boral Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,183
+14.86%
|
$101,013
$11.91 P/Share
|
|
Oct 19
2020
|
Mark Alan Goldberg |
SELL
Open market or private sale
|
Direct |
5,455
-60.5%
|
$572,775
$105.0 P/Share
|
|
Oct 19
2020
|
Mark Alan Goldberg |
BUY
Exercise of conversion of derivative security
|
Direct |
5,455
+37.69%
|
$103,645
$19.53 P/Share
|
|
Oct 16
2020
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
13,334
-8.54%
|
$1,346,734
$101.55 P/Share
|
|
Oct 16
2020
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
13,334
+19.18%
|
$480,024
$36.05 P/Share
|
|
Oct 07
2020
|
Mark Alan Goldberg |
SELL
Open market or private sale
|
Direct |
5,454
-60.49%
|
$545,400
$100.0 P/Share
|
|
Oct 07
2020
|
Mark Alan Goldberg |
BUY
Exercise of conversion of derivative security
|
Direct |
5,454
+37.69%
|
$103,626
$19.53 P/Share
|
|
Oct 07
2020
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
5,000
-3.41%
|
$495,000
$99.17 P/Share
|
|
Oct 07
2020
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.3%
|
$40,000
$8.8 P/Share
|
|
Oct 07
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
600
-5.67%
|
$60,000
$100.0 P/Share
|
|
Oct 07
2020
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
600
+5.36%
|
$4,800
$8.8 P/Share
|
|
Oct 06
2020
|
Marion Dorsch Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,600
-23.17%
|
$455,400
$99.0 P/Share
|
|
Oct 06
2020
|
Marion Dorsch Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,600
+18.81%
|
$170,200
$37.11 P/Share
|
|
Oct 01
2020
|
Fouad Namouni PRESIDENT, R & D |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+50.0%
|
-
|
|
Oct 01
2020
|
Nicholas Lydon |
SELL
Open market or private sale
|
Direct |
9,815
-7.43%
|
$902,980
$92.87 P/Share
|